Oculis Announces European Medicines Agency PRIME Designation for Privosegtor, Advancing a Potential First‐in‐Class Neuroprotective Candidate for Optic Neuritis

AI Briefing

• – Oculis Holding AG's neuroprotective candidate Privosegtor receives PRIME designation from EMA for treatment of optic neuritis.
• – Privosegtor aims to address a significant unmet medical need in ophthalmology and neuro-ophthalmology.
• – The designation is a key step towards advancing Privosegtor's development as a potential first-in-class neuroprotective candidate.